Clinical trial protocols MCQs With Answer

Clinical trial protocols are the backbone of compliant, ethical, and scientifically sound studies. For M. Pharm students specializing in Regulatory Affairs (MPH 104T), understanding protocol structures, regulatory requirements, and operational details is crucial for developing and reviewing trials that meet global standards. This set of MCQs focuses on the essential components of a protocol, from objectives, endpoints, and randomization to safety reporting, monitoring, and amendments. It integrates ICH-GCP concepts, practical design considerations, and regulatory expectations for submissions and oversight. Use these questions to test your grasp of protocol development, risk management, and quality by design principles. Each item is paired with the correct answer to aid quick revision and deeper conceptual clarity.

Q1. Which ICH-GCP section specifically outlines the required content of a clinical trial protocol?

• ICH E6(R2) Section 6
• ICH E2A
• ICH Q8
• WHO TRS 953 Annex 9

Correct Answer: ICH E6(R2) Section 6

Q2. Which detail is mandatory on the protocol title page to ensure version control and traceability?

• Protocol code number and version/date
• Investigator’s curriculum vitae
• Site budget and payment schedule
• Investigational product stability report

Correct Answer: Protocol code number and version/date

Q3. A protocol change implemented before IRB/IEC approval to remove an immediate hazard to subjects is termed:

• Urgent safety measure
• Non-substantial amendment
• Administrative letter
• Protocol deviation

Correct Answer: Urgent safety measure

Q4. The primary purpose of inclusion and exclusion criteria in a protocol is to:

• Ensure participant safety and define the target population
• Increase the total sample size
• Reduce overall trial costs
• Accelerate site activation timelines

Correct Answer: Ensure participant safety and define the target population

Q5. Which is the best example of a well-defined primary endpoint in a protocol?

• “Improvement in symptoms”
• “Change from baseline in HbA1c at Week 24 measured by HPLC”
• “Better quality of life”
• “Reduced hospitalizations”

Correct Answer: “Change from baseline in HbA1c at Week 24 measured by HPLC”

Q6. Randomization procedures described in a protocol should include:

• Allocation concealment method
• Names of randomized participants
• Sponsor’s marketing strategy
• Journal selection for publication

Correct Answer: Allocation concealment method

Q7. In a double-blind clinical trial, blinding typically applies to:

• Participants and investigators
• Sponsors and regulators
• CRO monitors and DMC members
• Pharmacists and data managers

Correct Answer: Participants and investigators

Q8. A Data Monitoring Committee (DMC) is most strongly recommended in trials that are:

• Large, long-duration, or high-risk in nature
• Single-dose Phase I (SAD) studies only
• Bioavailability/bioequivalence studies
• Postmarketing observational surveys only

Correct Answer: Large, long-duration, or high-risk in nature

Q9. For a fatal or life-threatening SUSAR, the sponsor’s standard regulatory reporting timeline is:

• 7 calendar days
• 15 business days
• 30 calendar days
• 48 hours

Correct Answer: 7 calendar days

Q10. A statistically sound sample size justification in a protocol requires, at minimum:

• Assumed effect size, variability, alpha level, and power
• Site start-up timelines and recruitment plan
• Investigator publication record
• Shipping conditions for the IMP

Correct Answer: Assumed effect size, variability, alpha level, and power

Q11. The schedule of assessments (schedule of events) in a protocol primarily serves to:

• Map trial visits and procedures across timepoints
• Present the product’s branding strategy
• Display site payment milestones
• List laboratory vendor addresses

Correct Answer: Map trial visits and procedures across timepoints

Q12. The informed consent section of a protocol should explicitly describe:

• The process for re-consent after amendments affecting participants
• The investigator’s bank account details
• The sponsor’s legal counsel contact
• Advertising taglines for recruitment posters

Correct Answer: The process for re-consent after amendments affecting participants

Q13. The protocol signature page for a multicenter trial is normally signed by:

• The sponsor (or designee) and the principal investigator
• The DMC chair and the regulatory assessor
• All study participants
• CRO monitors and site pharmacists

Correct Answer: The sponsor (or designee) and the principal investigator

Q14. A platform trial under a master protocol is best characterized by its ability to:

• Allow multiple therapies to enter or exit under a single overarching protocol
• Study a single therapy in a single disease only
• Conduct non-interventional observational analyses only
• Run standard two-period crossover BE assessments

Correct Answer: Allow multiple therapies to enter or exit under a single overarching protocol

Q15. Which adaptive feature is appropriate only if prospectively specified in the protocol (with type I error control)?

• Sample size re-estimation based on interim data
• Changing the primary endpoint after unblinded review without alpha control
• Dropping underperforming sites for slow enrollment
• Altering the drug synthesis route mid-trial

Correct Answer: Sample size re-estimation based on interim data

Q16. Which of the following constitutes a substantial protocol amendment?

• Changing the primary endpoint
• Correcting typographical errors
• Updating email addresses in the contact list
• Minor grammatical clarifications

Correct Answer: Changing the primary endpoint

Q17. Source Data Verification (SDV), as described in the monitoring section of a protocol, refers to:

• Checking case report form entries against original source records
• Recalculating sample size at study close
• Auditing sponsor financial statements
• Assessing commercial launch plans

Correct Answer: Checking case report form entries against original source records

Q18. For multiregional clinical trials (ICH E17), protocols should plan for:

• Prospectively planned pooled analysis with regional consistency assessment
• Separate protocols for every country without pooling
• The same dose across all populations regardless of PK/PD
• Exclusion of elderly populations by default

Correct Answer: Prospectively planned pooled analysis with regional consistency assessment

Q19. The investigational medicinal product (IMP) management section of a protocol should include:

• Accountability procedures and storage conditions
• Patent extension strategies
• Sales forecasting models
• Media engagement plan

Correct Answer: Accountability procedures and storage conditions

Q20. According to ICMJE requirements, the protocol should ensure trial registration occurs:

• Before enrollment of the first participant
• At database lock
• After the clinical study report is finalized
• At the time of regulatory submission

Correct Answer: Before enrollment of the first participant

Download